Back
Johnson & Johnson (JNJ)
PharmaceuticalsJNJ · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$270.24
+1.07%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$11.03
ROE
26.4%
Gross margin
68.0%
Debt/Equity
0.68x
Revenue growth
9.9%
Johnson & Johnson — company intelligence
Earnings surprises
Q2 2026$2.90 vs $2.87 est+0.9%
Q1 2026$2.70 vs $2.69 est+0.3%
Q4 2025$2.46 vs $2.46 est-0.1%
Q3 2025$2.80 vs $2.78 est+0.5%
Analyst consensus · 31 analysts
22 Buy9 Hold0 Sell
Updated Aug 7, 2026
Insider activity · 90 days
3 buys6 sellsnet -200,889 shares
Duato JoaquinSell 20,976 · Aug 13, 2026
Duato JoaquinSell 102,315 · Aug 13, 2026
Duato Joaquinother 123,291 · Aug 13, 2026
Recent SEC filings
4 — Insider transaction reportAug 18, 2026
4 — Insider transaction reportAug 14, 2026
4 — Insider transaction reportAug 7, 2026
Latest news
Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment — Benzinga · 22h ago
Reported Earlier, FDA Approves Johnson & Johnson's IMAAVY (Nipocalimab-Aahu) As First-Ever Treatment For Warm Autoimmune Hemolytic Anemia, Based On Pivotal Phase 2/3 ENERGY Study — Benzinga · 1d ago
Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push — SeekingAlpha · 3d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.